Treatment Permission Granted for Cancer Therapy in India
News Aug 16, 2007
The Berlin-based biotechnology company MOLOGEN AG has been informed by its license partner ONCO Life Sciences Pvt. Ltd. India, that the respective authorities have granted treatment permission for MOLOGEN’S cell-based gene therapy. This cancer therapy can currently be used for the treatment of renal cell carcinoma, colon, breast, and lung cancer.
At the end of 2006, MOLOGEN had granted licensing and marketing rights for its cancer therapy for India to ONCO Life Sciences. In the context of the agreement, MOLOGEN had received an upfront payment of EUR 2.1 million.
MOLOGEN will receive further payments for the supply of the individualized therapy components to ONCO Life Sciences. MOLOGEN has completed all necessary measures in the areas of production and logistics to provide immediate supply to India. The importation of the components will be free of customs duties.
In advance to the treatment permission, the network of Indian oncologists (ELITE Network) has been educated about the mode of action, the use and the advantages of MOLOGEN’S cell-based gene therapy. On the basis of single treatment permissions, first patients had been treated in Mumbai and Delhi.
"We are very pleased by the treatment permission for our individualized cell-based gene therapy against major cancer diseases", said Prof Burghardt Wittig, Chief Executive Officer of MOLOGEN AG.
"This innovative and straight-forward decision of the Indian Department of Biotechnology impressively confirms our development and commercialization concept for the cell-based therapy approach in the treatment of cancer. It could also serve as reference for further applications in other countries."
Researchers Discover Mutation That Appears to Protect Against Multiple Aspects of Biological AgingNews
The first genetic mutation that appears to protect against multiple aspects of biological aging in humans has been discovered in an extended family of Old Order Amish living in the vicinity of Berne, Indiana, report Northwestern Medicine scientists.READ MORE
Defects in Cell’s ‘Waste Disposal System’ Linked to Parkinson’sNews
An international study has shed new light on the genetic factors associated with Parkinson’s disease, pointing at a group of lysosomal storage disorder genes as potential major contributors to the onset and progression of this common neurodegenerative disorder.READ MORE
Mouse Model Demonstrates Potential of New Autism DrugNews
Scientists have performed a successful test of a possible new drug in a mouse model of an autism disorder. The candidate drug, largely corrected electrical, behavioral and brain abnormalities in the mice.READ MORE